Triple-action drug retatrutide delivers major weight loss for people with diabetes, Phase III trial finds

Дата публикации: 13-10-2026 14:20:37

A recent Phase III clinical trial, TRIUMPH-2, evaluated the efficacy and safety of retatrutide, a triple receptor agonist and experimental once-weekly injection being developed to treat obesity and type 2 diabetes. What sets it apart from drugs such as semaglutide (Wegovy), which targets one hormone, and tirzepatide (Zepbound), which targets two, is its ability to activate three hormone receptors at once.

Основное содержимое страницы с новостью.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Lilly's Triple Agonist, Retatrutide, Successful in Two Additional Phase 3 Obesity Trials, Delivering Significant Improvements in Weight and A1C	0	13.62	23-07-2026
2	Weight‑loss jabs may create a new kind of yo‑yo dieting	0	7	10-07-2026
3	Bofanglutide linked to meaningful reductions in HbA1c in adults with T2DM	5	7	02-07-2026
4	Time-Dependent Effects of GLP-1 Receptor Agonists on Weight Loss: A Systematic Review and Meta-Analysis of Phase 3 Trials [version 1; peer review: awaiting peer review]	0	13.63	08-08-2026
5	Eli Lilly's Mounjaro shows heart health benefits in head-to-head trial with older diabetes drug Trulicity	2	7	31-07-2025
6	Eli Lilly takes aim at illicit market for its experimental weight-loss drug	0	13.99	12-08-2026
7	Boehringer Ingelheim Strengthens Obesity Pipeline as Potential First-in-Class Triple Receptor Agonist BI 3034701 Enters Phase II Development	0	13.34	16-07-2026
8	<![CDATA[CagriSema Alters Food-Cue Responses, Reduces Organ Fat in New Analyses]]>	0	18.97	30-09-2026
9	Popular diabetes drug shown to lower inflammation, which may protect the heart	0	11.73	06-10-2026
10	Weight-loss pill designed to mimic exercise clears testing	0	12.57	22-08-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 10.14. Источник: medicalxpress.com.